// App-Quantinova.ai

: Final Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the MetAP2 Inhibitor ZGN-1061 in Patients with Type 2 Diabetes

Researchers

Presenter

  • TERRI KIM

Principal Investigators

  • DONGLIANG ZHUANG

  • TONYA L. HAUGEN

  • DENNIS D. KIM

Medical Centers

  • N/A

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Endocrine/metabolic Diseases (ME)

Disease

  • Venous thrombosis

  • Type 2 diabetes mellitus

  • Diabetes

Biomarkers

  • High sensitivity C-reactive protein

  • Body mass index

Drug/Treatment

  • methionine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved